This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (FORTE) is a colorectal cancer prevention study looking to answer the question: when should patients who had 1-2 small benign polyps (adenomatous polyps/adenomas) removed during colonoscopy have repeat surveillance colonoscopy?

This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone.

The purpose of the study is to compare the subcutaneous (SC) injection using an investigational wearable injector device to intravenous (IV) infusion of isatuximab in combination with pomalidomide and dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM).

This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone [R-miniCHOP]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma.